Fortis Healthcare Limited , a prominent player in the Indian healthcare sector, has initiated a postal ballot process to seek shareholder approval for the appointment of Dr. Keith Hsiu Chin Lim as a Non-Independent & Non-Executive Director on its Board. This move comes as part of the company's ongoing efforts to strengthen its leadership team and enhance corporate governance.

Key Details of the Appointment

• Nominee Director: Dr. Lim's nomination comes from Northern TK Venture Pte. Limited, signaling a strategic alignment with one of Fortis Healthcare's key stakeholders.
• Appointment Date: Dr. Lim was initially appointed as an Additional Director on September 09, 2025.
• Shareholder Approval: The company is now seeking ratification of this appointment through a postal ballot, in compliance with regulatory requirements.
• Voting Period: Shareholders can cast their votes from October 17, 2025, to November 15, 2025.
• Results Declaration: The outcome of the postal ballot is scheduled to be announced by November 18, 2025.

Professional Background of Dr. Keith Hsiu Chin Lim

Dr. Lim brings a wealth of experience to the Fortis Healthcare board:

• Current Role: Group Chief Medical Officer at IHH Healthcare
• Medical Qualifications:
  • MBBS from National University of Singapore
  • Fellow of the Royal Australian and New Zealand College of Radiologists
• Experience: Over 20 years as a radiation oncologist
• Academic Contributions: Previously served as Assistant Dean at the NUS School of Medicine
• Research Impact: His research has been cited over 2,000 times
• Funding Success: Secured over S$2.50 million in research funding

Previous Roles and Achievements

• Group Chief Value Officer at National University Health System (NUHS), Singapore
• Director of Clinical Outcomes and Value at Singapore's Ministry of Health
• Recipient of Singapore's National Medical Excellence Award

Implications for Fortis Healthcare

The appointment of Dr. Lim, with his extensive experience in healthcare management and policy, could potentially bring valuable insights to Fortis Healthcare's operations and strategic direction. His background in value-based healthcare and clinical quality improvement aligns well with the evolving healthcare landscape in India, where there is an increasing focus on quality care and cost-effectiveness.

Shareholders are encouraged to review the detailed postal ballot notice and exercise their voting rights on this important corporate action. The outcome of this vote will be crucial in shaping the future leadership of Fortis Healthcare Limited.

As the healthcare sector continues to evolve, especially in the wake of global challenges, the expertise of leaders like Dr. Lim may prove instrumental in navigating the complex landscape of healthcare delivery and management.

Fortis Healthcare shares witnessed a significant uptick, climbing 3% following a crucial development in its ownership structure. The catalyst for this surge was the Securities and Exchange Board of India (SEBI) granting approval to Malaysia-based IHH Healthcare Berhad to proceed with an open offer for acquiring an additional 26% stake in the Indian hospital chain.

Background of the Deal

IHH Healthcare's involvement with Fortis dates back to 2018 when it acquired a 31.1% stake for ₹4,000 crore. This acquisition was to be followed by an open offer worth ₹3,300 crore, initially scheduled for December 2018. However, legal complications involving Daiichi Sankyo and Fortis' former promoters, the Singh Brothers, led to a prolonged delay.

Legal Hurdles Cleared

The path for the open offer was finally cleared by the Supreme Court in September 2022, subject to SEBI's approval. This recent green light from SEBI marks a significant milestone in the long-drawn process.

Financial Implications

The original open offer price in 2018 was set at ₹170 per share. However, Fortis' share price has seen a remarkable appreciation since then:

At current market prices, the size of the open offer would amount to approximately ₹19,308 crore, significantly higher than the initial ₹3,300 crore planned in 2018.

Recent Performance

Fortis Healthcare's stock has shown strong momentum:

This recent approval and the subsequent share price movement reflect positive investor sentiment towards Fortis Healthcare. The completion of this long-pending open offer could potentially lead to a change in the company's ownership structure, which investors will be keenly watching in the coming days.

As always, investors are advised to conduct their own research and consider their financial goals before making investment decisions based on this development.